Core Viewpoint - The stock of HAPO Pharmaceutical-B (02142) has increased by over 3%, currently trading at 12.67 HKD with a transaction volume of 30.48 million HKD, following the announcement of a successful project approval related to pancreatic cancer research [1] Group 1: Company Developments - HAPO Pharmaceutical has been actively involved in the research and development of innovative antibody therapies focused on oncology and immune diseases [1] - The company utilizes its proprietary technology platform, Harbour Mice®, to develop over 20 product pipelines, including bispecific antibodies, multi-specific antibodies, and antibody-drug conjugates (ADCs) [1] - HAPO has established deep collaborations with several global pharmaceutical companies, including AstraZeneca, Pfizer, Bristol-Myers Squibb, Otsuka Pharmaceutical, AbbVie, and Moderna, which highlights the recognition of its technological capabilities [1] Group 2: Research Initiatives - The project titled "Research on the Pathogenesis and Clinical Precision Diagnosis and Treatment Paradigm of Pancreatic Cancer," led by Shanghai Changzheng Hospital and involving HAPO Pharmaceutical, has been officially approved under the National Science and Technology Innovation 2030 initiative [1] - The company is advancing innovative therapies targeting CLDN18.2 and LIFR, which have entered clinical or application stages, thereby diversifying its treatment options for pancreatic cancer [1]